Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Triulzi, Tiziana"'
Autor:
Giussani M; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori di, 20133 Milano, Italy. marta.giussani@istitutotumori.mi.it., Triulzi T; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori di, 20133 Milano, Italy. tiziana.triulzi@istitutotumori.mi.it., Sozzi G; Tumor Genomics Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori di, 20133 Milano, Italy. gabriella.sozzi@istitutotumori.mi.it., Tagliabue E; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori di, 20133 Milano, Italy. elda.tagliabue@istitutotumori.mi.it.
Publikováno v:
Cells [Cells] 2019 Jan 23; Vol. 8 (2). Date of Electronic Publication: 2019 Jan 23.
Autor:
Huber V; Unit of Immunotherapy of Human Tumors, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy. Electronic address: veronica.huber@istitutotumori.mi.it., Camisaschi C; Unit of Immunotherapy of Human Tumors, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Berzi A; Unit of Immunotherapy of Human Tumors, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Ferro S; Unit of Immunotherapy of Human Tumors, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Lugini L; Department of Oncology and Molecular Medicine, National Institute of Health, Viale Regina Elena 299, 00161 Rome, Italy., Triulzi T; Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Amadeo 42, 20133 Milan, Italy., Tuccitto A; Unit of Immunotherapy of Human Tumors, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Tagliabue E; Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Amadeo 42, 20133 Milan, Italy., Castelli C; Unit of Immunotherapy of Human Tumors, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy., Rivoltini L; Unit of Immunotherapy of Human Tumors, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.
Publikováno v:
Seminars in cancer biology [Semin Cancer Biol] 2017 Apr; Vol. 43, pp. 74-89. Date of Electronic Publication: 2017 Mar 06.
Autor:
Castiglioni F; Molecular Targeting Unit, Department of Experimental Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy., Terenziani M, Carcangiu ML, Miliano R, Aiello P, Bertola L, Triulzi T, Gasparini P, Camerini T, Sozzi G, Fossati-Bellani F, Ménard S, Tagliabue E
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2007 Jan 01; Vol. 13 (1), pp. 46-51.
Autor:
Triulzi, Tiziana
Despite the clinical benefit of trastuzumab, some patients do not respond to this therapy. Aims of this study are to identify new predictive biomarkers to distinguish responsive from de novo resistant tumours and to have new insights into the biologi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5905d3870a4ad0792ddad1a0e132934
Autor:
Maria Rosa Cappelletti, Elda Tagliabue, Loris De Cecco, Martina Di Modica, Tiziana Triulzi, Daniele Generali, Serena Di Cosimo, Biagio Paolini, Pier Luigi Lollini, Viola Regondi, Lucia Sfondrini
Publikováno v:
British Journal of Cancer
Background: Optimising the selection of HER2-targeted regimens by identifying subsets of HER2-positive breast cancer (BC) patients who need more or less therapy remains challenging. We analysed BC samples before and after treatment with 1 cycle of tr
Autor:
Silvana Canevari, Andrea Balsari, Sylvie Ménard, Serena Di Cosimo, Marta Giussani, Aleix Prat, Marialuisa L. Carcangiu, Manuela Campiglio, Daniele Generali, Biagio Paolini, Elda Tagliabue, Loris De Cecco, Alberto Bottini, Tiziana Triulzi, Marco Sandri
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
Oncotarget
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
Oncotarget
While results thus far demonstrate the clinical benefit of trastuzumab, some patients do not respond to this therapy. To identify a molecular predictor of trastuzumab benefit, we conducted whole-transcriptome analysis of primary HER2+ breast carcinom
Autor:
Daniele Generali, Tiziana Triulzi, Giulia Bianchi, Gabriella Mariani, Andrea Balsari, Viola Regondi, Elda Tagliabue, Barbara Oliviero, Martina Di Modica, Stefania Varchetta, Lucia Sfondrini
Publikováno v:
Scopus-Elsevier
Oncotarget
Oncotarget
Recent clinical data indicate a synergistic therapeutic effect between trastuzumab and taxanes in neoadjuvantly treated HER2-positive breast cancer (BC) patients. In HER2+ BC experimental models and patients, we investigated whether this synergy depe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c43dc35ae941efe5eae0d489f8df08b1
http://www.scopus.com/inward/record.url?eid=2-s2.0-84995511494&partnerID=MN8TOARS
http://www.scopus.com/inward/record.url?eid=2-s2.0-84995511494&partnerID=MN8TOARS